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Abstract
Apolipoprotein (APOE) e4 genotype is an accepted risk factor for accelerated cognitive aging and dementia, though its
neurostructural substrates are unclear. The deleterious effects of this genotype on brain structure may increase in magnitude into
older age. This study aimed to investigate in UK Biobank the association between APOE e4 allele presence vs. absence and brain
imaging variables that have been associated with worse cognitive abilities; and whether this association varies by cross-sectional age.
We used brain magnetic resonance imaging (MRI) and genetic data from a general-population cohort: the UK Biobank (N = 8395
after exclusions). We adjusted for the covariates of age in years, sex, Townsend social deprivation scores, smoking history and
cardiometabolic diseases. There was a statistically significant association betweenAPOE e4 genotype and increased (i.e. worse) white
matter (WM) hyperintensity volumes (standardised beta = 0.088, 95% confidence intervals = 0.036 to 0.139, P = 0.001), a marker of
poorer cerebrovascular health. There were no associations with left or right hippocampal, total grey matter (GM) orWM volumes, or
WM tract integrity indexed by fractional anisotropy (FA) and mean diffusivity (MD). There were no statistically significant interac-
tions with age. Future research in UK Biobank utilising intermediate phenotypes and longitudinal imaging hold significant promise
for this area, particularly pertaining to APOE e4’s potential link with cerebrovascular contributions to cognitive aging.
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Introduction
Variation at the APOE genetic locus is an established risk factor
for Alzheimer’s disease (AD) (Lutz et al. 2010), and cognitive
decline in domains of memory, information processing speed
and overall cognitive function (‘g’) (Wisdom et al. 2011). The
e4 allele, which typically has a frequency of around 15% in
Caucasian/European populations (Eisenberg et al. 2010), is
known as the ‘risk’ allele, vs. the neutral e3 allele (typical
frequency 78%) and possibly protective e2 allele (frequency
6%). The APOE locus’s main function relates to lipid/
cholesterol metabolism, which is pleiotropic for several biolog-
ical functions including neuronal migration, axon guidance,
and the clearance of amyloid beta plaques – which characterise
AD - in the brain (Holtzman et al. 2012).
There is evidence that the effects of APOE e4 variation on
brain functioning increase across the lifespan, i.e. differences
between e4 carriers vs. non-carriers in terms of cognitive ability
become more pronounced with older age regardless of outright
dementia (Schiepers et al. 2011). Davies et al. (2015) reported
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data from the CHARGE consortium where in 53,949 European
participants from 31 different cohorts (aged >45 years and non-
demented), the strength of association between rs10119 (in the
APOE genetic region) and a general factor of fluid cognitive
function, increased linearly with the mean age of each cohort
(Pearson’s r= −0.42, P = 0.022). Similarly, a report that included
data from the Generation Scotland cohort (Marioni et al. 2015)
(n= 18,337) reported significant negative associations between
APOE e4 allele presence and tests scores on Logical memory
(standardized beta =−0.095, P = 0.003), and Digit symbol cod-
ing (standardized beta = −0.087, P = 0.004); however this was
only significant in participants aged 60 years or over.We recently
investigated potential APOE e4 genotype-by-age interaction on
cognitive function in UK Biobank (n = ~111 k) (Lyall et al.
2016b); there were no statistically significant interactions; how-
ever there are concerns over the potential imprecision and reli-
ability in the novel UK Biobank baseline cognitive tests (Lyall
et al. 2016a), whichmeans that result may be an underestimate of
the potential true effect. Overall, recent research warrants further
study into the potential structural brain substrates of theAPOE e4
effect into older age.
It is important to understand the neurobiological underpin-
nings of the potential age-related deleterious effects of APOE
e4 on brain function. The integrity of connectiveWM tracts in
the brain is associated with overall cognitive function (Penke
et al. 2012). The hippocampus is a known brain substrate of
memory loss, one of the key symptoms of AD, and is the first
site to show evidence of amyloid beta plaques (Reilly et al.
2003). Total brain volumes, including total GM and WM vol-
umes are significantly associated with changes in cognitive
function (Royle et al. 2013). Brain WM hyperintensities are
a major substrate of age-related cognitive decline and cerebro-
vascular disease (Debette and Markus 2010), and common in
AD (Paternoster et al. 2009).
Investigating associations between APOE genotype and MRI
markers is a topic of intense research, but studies involving struc-
tural neuroimaging parameters have not produced consistent re-
sults (Scarmeas and Stern 2006). Whereas e4 carriers appear to
be at increased risk of hippocampal atrophy (Manning et al.
2014), worse WM microstructural integrity (Slattery et al.
2017) and selective GM atrophy (Pievani et al. 2009) in the
context of pathological aging (such as AD and mild cognitive
impairment), there is less clarity with respect to MRI markers in
non-pathological aging. For example, null associations are re-
ported for APOE genotype and cross-sectional hippocampal vol-
ume (Ferencz et al. 2013; Jack et al. 1998; Killiany et al. 2002;
Lyall et al. 2013; Manning et al. 2014; Schuff et al. 2009), brain
atrophy (Cherbuin et al. 2008), GM volume (Cherbuin et al.
2008) and someWMmeasures (Lyall et al. 2014, 2015), though
APOE e4 carriers exhibited greater WM hyperintensity growth
over a 3-year period in older age when compared to non-e4
carriers (Cox et al. 2017). A meta-analysis (n = 8917) reported
that e4 genotype is associated with greater burden of MRI
markers associated with cerebrovascular disease (cerebral
microbleeds (Schilling et al. 2013)).However,many prior studies
possess low statistical power with which to detect subtle effects
specifically in mid- and later-life, and thus it is unclear whether
APOE status is unrelated to non-pathological brain aging, or
whether subtler differences exist which prior studies have been
unable to reliably quantify. It is possible on the other hand that
APOE e4 has a stable association with poorer brain health which
is not more pronounced in older age (Heise et al. 2011).
The UK Biobank cohort is a large prospective cohort of
whom at the time of writing around 13,000 have genetic and
MRI data (prior to exclusions). This report aims to test for an
effect of APOE e4 genotype carrier status on specific brain im-
aging phenotypes in UK Biobank, and whether that association
interacts with age. The large sample N improves the potential
reliability of association estimates herein, comparedwith smaller
reports as well as statistical power to detect small effects. We
examined several specific brain imaging phenotypes based on a-
priori hypotheses described above: left and right hippocampal
volumes, total GM and WM volumes, WM hyperintensity vol-
umes, and brain white matter tract integrity metrics.
It is hypothesized that for each brain phenotype, the associ-
ation between APOE e4 genotype will be in the deleterious
direction (i.e. lower scores for all except WM hyperintensity
volumes and tract mean diffusivity, for which higher scores
are worse), and interact with age where the association becomes
larger in older participants (on average). We assessed the phe-
notypes of: two latent measures of WM tract integrity derived
from tract-specific FA (‘gFA’) andMD (‘gMD’); total GM; total
WM; total WM hyperintensity volume and hippocampal vol-
umes (all volumes in millimetres3). This will enable us to quan-
tify, with considerable statistical power whether the effect of
APOE e4 genotype on brain phenotypes of relevance to cogni-
tive decline and AD is stronger in older age.
Methods
Study design and participants
The UKBiobank cohort is a large prospective cohort of 502,628
participants with phenotypic information. All participants
attended one of 22 assessment centres from 2006 to 2010 where
they completed a series of physical, sociodemographic, andmed-
ical assessments (Sudlow et al. 2015). In 2014, MRI scanning of
baseline participants began, and this is ongoing until around
100,000 participants have been scanned. As of November
2017, n = 12,931 have MRI data derived by UK Biobank.
Genetic data
UK Biobank genotyping was conducted by Affymetrix using
a bespoke BiLEVE Axiom array for ∼50,000 participants and
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the remaining ∼450,000 on the Affymetrix UK Biobank
Axiom array. All genetic data were quality controlled by UK
Biobank (Bycroft et al. 2017). The APOE e genotype is di-
rectly genotyped. Further information on the genotyping pro-
cess is available (http://www.ukbiobank.ac.uk/scientists-3/
genetic-data), including detailed technical documentation
(https://biobank.ctsu.ox.ac.uk/crystal/docs/genotyping_
sample_workflow.pdf). The two APOE e SNPs – rs7412 and
rs429358 – were both in Hardy Weinberg equilibrium (P > 0.
05) assessed with PLINK V1.90 (Purcell et al. 2007).
MRI data
An average of four years after initial recruitment, a subset of
UK Biobank participants also underwent head MRI on the
same scanner at a single site (Cox et al. 2016). The release
of brain MRI data as of August 2017 is the subject of the
current study. All brain imaging data used here was processed
and quality checked by UK Biobank (Alfaro-Almagro et al.
2017; Miller et al. 2016) and available in the form of Imaging
Derived Phenotypes (IDPs). Details on the UK Biobank im-
aging acquisition and processing including WM/GM and hip-
pocampal segmentation, and on theWMdiffusion processing,
are freely available from three sources: the UK Biobank pro-
tocol: http://biobank.ctsu.ox.ac.uk/crystal/refer.cgi?id=2367
and documentation: http://biobank.ctsu.ox.ac.uk/crystal/refer.
cgi?id=1977 and has been described elsewhere (Cox et al.
2016; Miller et al. 2016). The total WM and GM variables
were segmented automatically using FAST (Zhang et al.
2001) and were normalised for skull size based on the T1
MR scan (see open-access MRI protocol, pp.11; https://
biobank.ctsu.ox.ac.uk/crystal/docs/brain_mri.pdf). Total WM
hyperintensity volumes were calculated based on T1 and T2
FLAIR, derived by UK Biobank using the Brain Intensity
Abnormality Classification Algorithm (BIANCA) (Griffanti
et al. 2016) with the procedure detailed by Miller et al.
(2016). WM hyperintensity volumes were log-transformed
here due to a positively skewed distribution.
FA andMD are commonly-derivedWM tract integrity var-
iables which describe the directional coherence and magni-
tude of water molecule diffusion, respectively. Water mole-
cules tend to diffuse with greater directional coherence and
lower magnitude when constrained by tightly-packed fibres
(such as well-myelinated axons) as well as by cell membranes,
microtubules and other structures; lower FA and higher MD
are generally considered to reflect poorer/less ‘healthy’ white
matter (Jones et al. 2013). We constructed general factors of
FA (gFA) and MD (gMD) using principal components analy-
sis based on 22 tracts (Cox et al. 2016). These general mea-
sures reflect the high degree of shared microstructural proper-
ties across major white matter tracts in the brain; as found in
this cohort, and various other groups (Alloza et al. 2016; Cox
et al. 2016; Penke et al. 2012; Telford et al. 2017). Inspection
of eigenvalues showed clear single unrotated factor solutions
for gFA (eigenvalue = 12.83, r2 = 58%) and gMD (eigenval-
ue = 13.76, r2 = 63%). All brain MRI metrics were trans-
formed into Z-scores based on the final analysis sample to
ease interpretation.
Covariates
UK Biobank derived a Townsend deprivation score for all
participants immediately prior to baseline; calculated from
data on car ownership, household overcrowding, owner-
occupation and unemployment aggregated for postcodes of
residence (Townsend 1998). Higher Townsend scores equate
to higher levels of area-based socioeconomic deprivation.
Participants were asked during the baseline and MRI assess-
ments about any previous or current cardiometabolic condi-
tions that had been diagnosed by their doctor. Specifically,
participants were asked whether their doctor had diagnosed
each of myocardial infarction, angina, hypertension, diabetes
or stroke (individually).We defined CHD as either myocardial
infarction (MI) or angina. Smoking was classified as never,
previous, or current smoker based on self-report; we simpli-
fied this into a binary ever (previous plus current) vs. never
variable. We excluded participants that stated only ‘prefer not
to answer’ for disease and smoking variables: less than 1% of
the sample.
Exclusions
There were 12,662 participants with APOE e genotype and
brain MRI data. We excluded participants with non-white
British ancestry, self-report vs. genetic sex mismatch, putative
sex chromosomal aneuploidy, excess heterozygosity, and
missingness rate > 0.1. This left n = 11,065. We removed par-
ticipants who reported a neurological condition at baseline or
scan visit (~5%; Supplementary Table 1); the inclusion of
which could drive type-1 errors due to skewed results. We
accounted for relatedness between participants by selecting
one random participant for analysis from sets where two or
more individuals were 1st cousins or closer. This left 8395
participants for whom genotype frequencies of APOE e were
e2/e2 n = 48 (1%), e2/e3 n = 1032 (12%), e2/e4 = 208 (2%),
e3/e3 = 4960 (59%), e3/e4 n = 1958 (23%) and e4/e4 n = 189
(2%). As a check, participants were split into age groups (un-
der 50; 50 to 59; 60 and over): a chi square test showed no
significant difference in e4 frequency (p = 0.148). These sta-
tistics are shown in Supplementary Table 2.
Analysis
We used an e4+ dominant model of e3/e4 and e4/e4 collated
vs. e2/e2, e2/e3 and e3/e3 collated; e2/e4 is usually removed
because it has potentially risk and protective alleles (Wisdom
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et al. 2011). We elected for an e4 dominant (i.e. present vs.
absent) rather than dose model (i.e. 0/1/2) because there were
relatively few e4 homozygotes. We ran two linear regression
models to examine associations between e4 genotype and
each of the brain imaging parameters: gFA scores, gMD
scores, left/right hippocampal volume, total GM, total WM
and log WM hyperintensity volumes in mm3, each trans-
formed to Z-scores. For the ‘partially adjusted model’ we ad-
justed for age, genetic array, 8 principal components (PCs)
and sex. (The PCs were added conservatively to account for
possible population stratification, although this made no dif-
ference to the results in terms of APOE e4). For the ‘fully
adjusted model’ we then additionally adjusted for Townsend
deprivation scores, ever vs. never smoking cigarettes, and
self-reported doctor diagnosis of diabetes, hypertension and
CHD. For interaction models we added the requisite e4*age
interaction term. Finally, we re-ran analyses with added age2
and an e4*age2 interaction term to capture potentially curvi-
linear relationships.
We determined an alpha level of P < 0.05 as nominal signif-
icance, and corrected for multiple comparisons with the false
discovery rate (FDR) using a specialized program (Pike
2011). We calculated statistical power using G*power 3
(Faul et al. 2007). We conducted two additional post-
hoc sensitivity analyses: firstly, we adjusted for X/Y/Z-
coordinates of brain position during scanning, because it
was available in only n = 6647 participants. Secondly,
we adjusted the final results for baseline assessment
centre (one of 22 across the United Kingdom), to reduce
the possibility of any systematic procedural differences e.g.
handling of blood samples (although note that the MRI scan-
ning data we report on here was single-site).
A significant effect of e4 allele presence vs. absence would
indicate mean level differences in the brain parameter of in-
terest as a function of APOE e genotype (vs. absence) cross-
sectionally. A significant interaction with age (or age2) would
be consistent with a hypothesis of greater (i.e. accelerating)
decline with increasing age, according to APOE e4 allele pres-
ence vs. absence.
Results
Descriptive statistics are shown in Table 1, including chi
square (for ordinal/categorical data) and ANOVA (for contin-
uous data) tests of differences between APOE e4 pres-
ence vs. absence groups. There were 8395 participants
(mean age = 61.55, SD = 7.03, range = 46–73), of whom
3953 were male (46.1%). G*Power 3 showed we had
99% power to find a standardised effect size of Cohen’s
d = 0.1 (where 0.2 is considered small) for significant
associations or interactions, based on our e4 present vs. absent
sample sizes.
There were no associations between APOE e4 and gFA,
gMD (Table 2), left/right hippocampal volumes, total GM or
total WM both normalised for skull size: indicating no mean-
level difference in these brain parameters across the sample.
There was a significant association between APOE e4 posses-
sion and greater WM hyperintensity volume (fully-adjusted
standardised beta = 0.088, 95% CI = 0.036 to 0.139, P =
0.001). There were no significant e4*cross-sectional age in-
teractions at P < 0.05. Results were unchanged when we
added an age2 term (i.e. non-linear), adjusted for X/Y/Z-coor-
dinates of brain position during MRI scanning, or baseline
assessment centre. The e4 allele present vs. absent association
was generally similar when we additionally corrected theWM
hyperintensity volumes for total brain volume (total raw GM
plus total raw WM): fully-adjusted standardised beta = 0.083,
95% CIs = 0.032 to 0.134, P = 0.001.
Note that Table 1 shows a significant difference between e4
absent vs. present in terms of total GM (P = 0.002), although
this did not survive correction for relevant confounders (e.g.
age and sex; see Table 2).
As additional exploratory analyses, we analysed the 22
individual tract-specific FA/MD values identified as most sen-
sitive to age (Cox et al. 2016). There was one specific signif-
icant association, such that e4 carriers tended to have worse
FA of the tract forceps major (fully adjusted standardised be-
ta = −0.078, 95% CI = −0.138 to −0.018, P = 0.011).
However, there were no e4 associations with MD, nor any
interactions between e4 and age/age2 on FA/MD (P value
range otherwise = 0.108 to 0.994; data available upon re-
quest). We re-ran the nominally significant e4 present vs. ab-
sent association with WM hyperintensity volumes, as an
e4/e4 vs. non-e4 model: this was statistically significant
(fully-adjusted model standardised beta = 0.217, 95%
CI = 0.066 to 0.368, P = 0.005), with the caveat that
there were relatively few e4 homozygotes (n = 189).
The e4 allele present vs. absent association with WM
hyperintensity volumes remained significant when corrected
for type 1 error with FDR (fully adjusted q-value = 0.038) but
the association with tract forceps major FA did not (fully ad-
justed q-value >0.05).
Supplementary Table 3 shows that compared with the full
UK Biobank sample (after appropriate quality controlling as
described in the methods), the imaging sample here had a
similar frequency of APOE e4 but was slightly less deprived
(imaging Townsend mean = −2.02, SD = 2.58 vs. -1.58, SD =
2.92, P < 0.001). Table 1 shows no significant effect of e4
presence vs. absence on log WM hyperintensity volumes, al-
though this was significant in adjusted models. The main rea-
son for this was the statistical adjustment for age at assessment
(age at assessment vs. log hyperintensity volume standardised
beta in multivariate fully adjusted model = 0.06, 95% CI =
0.06 to 0.07, P < 0.001), i.e. that when age was accounted
for, there was a significant e4 effect. Full final model statistics
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are shown in Supplementary Table 4 and indicate that the e4/
hyperintensity volume association was also independent of
significant deleterious effects of male sex, diabetes, hyperten-
sion and smoking history.
Discussion
This report examined the potential association between APOE
e4 genotype and brain imaging phenotypes of relevance to
Table 2 Associations between APOE e4 presence and brain MRI variables (uncorrected for type-1 error)
Partially adjusted Fully adjusted
b Lower 95% CI Upper 95% CI p b Lower 95% CI Upper 95% CI p
Association with APOE e4 presence
gFA −0.034 −0.092 0.024 0.255 −0.034 −0.092 0.025 0.259
gMD 0.027 −0.030 0.085 0.352 0.026 −0.031 0.084 0.369
Left hippocampus −0.005 −0.058 0.049 0.861 −0.003 −0.057 0.051 0.911
Right hippocampus −0.005 −0.058 0.048 0.858 0.002 −0.052 0.055 0.954
Total GM (normalised) 0.012 −0.031 0.055 0.585 0.010 −0.033 0.053 0.645
Total WM (normalised) 0.029 −0.025 0.082 0.294 0.019 −0.035 0.072 0.496
Total WM hyperintensities 0.093 0.041 0.145 4 × 10−4 0.088 0.036 0.139 0.001
APOE e4*age interaction
gFA <0.001 −0.008 0.008 0.985 <0.001 −0.008 0.009 0.924
gMD 0.002 −0.006 0.010 0.661 0.001 −0.007 0.009 0.768
Left hippocampus −0.004 −0.012 0.003 0.252 −0.004 −0.012 0.004 0.291
Right hippocampus −0.004 −0.012 0.004 0.308 −0.004 −0.011 0.004 0.342
Total GM (normalised) 0.001 −0.005 0.007 0.842 0.001 −0.005 0.007 0.638
Total WM (normalised) −0.004 −0.011 0.004 0.340 −0.004 −0.012 0.003 0.258
Total WM hyperintensities −0.001 −0.008 0.006 0.816 −0.002 −0.009 0.005 0.614
Partially adjusted: APOE e4 presence vs. absence plus 8 genetic principal components, assessment centre, genetic array, age in years and sex. Bold
typeface denotes p < 0.05. Fully adjusted: (also) Townsend deprivation scores, self-reported diagnosed diabetes; hypertension; coronary heart disease,
ever vs. never smoking.
GM grey matter;WMwhite matter; FA fractional anisotropy;MDmean diffusivity; b standardised beta; CI confidence interval; APOE apolipoprotein e;
MRI magnetic resonance imaging
Table 1 Descriptive statistics
e4 absent (N = 6040; 74%) e4 present (N = 2147; 26%) Effect size P value
Demographic/lifestyle variables
Age in years, mean (SD) 61.66 (7.03) 61.19 (7.04) 0.07 0.009
Gender, male N (%) 2916 (48.28) 941 (43.83) 0.04 <0.001
Townsend score, mean (SD) −2.035 (2.58) −1.98 (2.58) 0.02 0.367
Smoking history, ever N (%) 2249 (40.32) 848 (39.55) 0.07 0.536
Brain MRI values
Left hippocampal volume (mm3) 3821.69 (468.75) 3814.99 (446.79) 0.01 0.613
Right hippocampal volume (mm3) 3933.61 (480.72) 3924.82 (478.75) 0.02 0.521
Normalised total grey matter (mm3) 796,681.00 (47,417.56) 800,931.70 (46,699.26) 0.09 0.002
Normalised total white matter (mm3) 711,833.90 (40,033.25) 713,252.30 (41,790.69) 0.04 0.220
White matter hyperintensity vol. (mm3) [before log-transform] 3517.85 (4480.04) 3710.22 (4657.41) 0.04 0.157
Disease prevalence rates
Coronary heart disease N, % 194 (3.22) 59 (2.75) 0.01 0.287
Hypertension N, % 1387 (22.99) 492 (22.95) <0.01 0.971
Diabetes N, % 298 (4.97) 85 (4.00) 0.02 0.067
Effect size = Cohen’s d for continuous data; Cramer’s V for frequency data
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cognitive aging and dementia. We have previously reported
on the baseline cognitive data fromUKBiobank (n = 111,739)
and reported generally no APOE e4*age interaction (Lyall
et al. 2016b), although the sensitivity of the tests used is un-
clear because they were novel, very brief, and suffered a de-
gree of floor effects (Lyall et al. 2016a). We expected the brain
imaging phenotypes to be more sensitive to age-related differ-
ences conditioned on APOE genotype. In terms of addition to
the literature, this study is the largest single-site study of
APOE e4 genotype and brain imaging metrics which are as-
sociated with cognitive aging.
With respect to our hypotheses, there was an association
between APOE e4 genotype and significantly increased WM
hyperintensity volume, such that e4 carriers exhibited 0.09
SDs greater load than non-carriers, and e4/e4 homozygotes
around 0.22 SDs; this reinforces findings in a smaller meta-
analysis (e.g. n = 4024) (Schilling et al. 2013). One limitation
of our data is that the exact mechanisms which lead to
rarefication of white matter tissue, are unclear, and may be
due to different causes in different people (Wardlaw
et al. 2013). The lack of a significant interaction with
age provided no evidence that this effect was stronger at
older ages; i.e. it was not the case that age and e4
genotype were synergistic. We found no significant as-
sociations or age interactions for APOE e4 with gFA,
gMD, total GM, WM, or hippocampal volumes. The cross-
sectional age range in the current sample, where most partic-
ipants were aged 50 to 70 years, may limit our ability to find a
significant interaction with age.
We found no significant interaction between cross-
sectional older age, APOE e4 genotype and worse WM tract
integrity (indexed by gFA/gMD) in around 8000 middle to
older-aged adults. This is an unusually large non-consortium,
single-scanner imaging genetics study, which allowed rela-
tively high statistical power to reliably detect small effects;
however we did not find any significant APOE e4 genotype-
by-age interactions.
During exploratory analyses, we did find one relatively
novel APOE e4 association with a specific tract FA value –
namely in the tract forceps major. It is interesting that this tract
was not assessed in the previously largest APOE e4/MRI
study, using the Lothian Birth Cohort 1936 (n = 650) (Lyall
et al. 2014). This demonstrates the importance of assessing as
many specific WM tracts as can be reliably identified in im-
aging studies of APOE e genotype, and may indicate some
differential sensitivity of some tracts (Cox et al. 2016; Lyall
et al. 2014). This association did attenuate when corrected for
type-1 error and may therefore be spurious. It is however
worth noting that brain MRI phenotypes are usually strongly
correlated (Cox et al. 2016) and generally speaking this can
potentially make adjustment for type-1 overly cautious in
some circumstances; independent replication in different co-
horts is advised (Pike 2011).
We generally found no significant e4 genotype-by-age
interactions on total GM, total WM, left or right hippocam-
pal volumes or total WM hyperintensity volume. This is in
line with some other findings; Lyall et al. (2013) reported
that of six relatively large (N range 198 to 949) studies
which examined APOE e4 genotype and hippocampal vol-
umes, only two were statistically significant at P < 0.05.
Generally, there is no evidence of a main effect of APOE
e4 on GM volume in non-demented adults (Cherbuin et al.
2008). In terms of WM hyperintensities, one meta-analysis
reported no significant association (n = 7351) however
most studies were of observer-rated WH hyperintensities
e.g. Fazekas scores (Paternoster et al. 2009) while another
d id repor t an assoc ia t ion wi th con t inuous WM
hyperintensity volumes (n = 8917) (Schilling et al. 2013)
(standardised beta = 0.047, 95% CI = 0.0006 to 0.094, P =
0.05). Our results are therefore mostly in line with a gener-
ally null association between APOE e4 and cross-sectional
brain volumes in middle age (around 60 years), but not WM
hyperintensity volumes and this may suggest that at least
part of APOE e4’s contribution to worse cognitive ability is
via a cerebrovascular-type pathway; although the findings
may also to an extent be secondary to prodromal AD.
While our findings are based on principally non-demented
middle to older aged individuals, they are supportive of a
vascular route from APOE e4 genotype to worse cognitive
abilities. The vascular hypothesis of AD suggests significant
cardiometabolic contributions to early AD neuropathology,
particularly amyloid beta (Janota et al. 2016). It is possible
that prodromal AD has not been fully accounted for in the
current sample, although very few participants self-reported
dementia at assessment.
In terms of limitations, this study tested for a cross-sectional
effect of increasing age on brain WMmicrostructure and struc-
tural morphology; a longitudinal within-participants design
may be more informative because it would minimize cohort
effects associated with being born in different time periods
(Anstey et al. 2003). UK Biobank will ultimately conduct lon-
gitudinal scanning in ~10,000 participants (Miller et al. 2016).
The participants in the current study were of generally good
health; we excluded participants who self-reported neurodegen-
erative diseases or those likely to affect the brain. However
these diagnoses are not validated medically and we therefore
cannot be certain of their accuracy; a recent analysis of self-
reported rheumatoid arthritis in UK Biobank showed that only
around half of participants that reported the chronic illness were
on relevant medication, which puts the validity of the diagnoses
into question (Siebert et al. 2016). Our analyses looked at rel-
atively non-specific brain imaging phenotypes, as compared
with for example hippocampal-subfields. Future studies will
expand the range of phenotypes, as well as including a larger
sample N once more UK Biobank participants have been
scanned and their data released.
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There may be some selection bias in the current sample,
where primarily healthier older participants are likely to re-
spond positively to invitation and attend assessment. It is also
possible that this occurs across the whole sample with regards
socioeconomic status, whereby more middle-class, profes-
sional people are liable to participate; we attempted to correct
for this with Townsend scores however these are proxies for
deprivation rather than being based on individual-level data.
Generally, the rate of participants with exclusionary diseases
were similar to the full UK Biobank cohort of approximately
500,000 – suggesting little bias in that regard between partic-
ipants that attended baseline assessment from 2006 to 2010,
vs. MRI scanning more recently. The current sample was
slightly less deprived than the full UK Biobank dataset of n
approximately 500,000. There may also be a degree of surviv-
al bias where the APOE e4 by age interaction is
underestimated because the older people with a more delete-
rious effect of e4 are more likely to be missing (Heffernan
et al. 2016): we saw no significant difference in e4 frequency
by age group (<50; 50–59; ≥60) although there was a small
but significant overall continuous effect where the e4 carriers
were on average around half-a-year younger.
This report examined the effects of APOE e4 genotype on
specific known substrates of worse cognitive aging however it
was not totally exhaustive. For example, we did not investi-
gate some brain phenotypes that have been reported to under-
lie some cognitive deficits, such as cortical thickness (Karama
et al. 2014) nor did we examine structural brain metrics totally
systematically and agnostically, e.g. voxel-based morphome-
try. Future research will take this more hypothesis-free ap-
proach in investigating APOE e4’s links to brain structure
and its relevance to cognitive abilities.
Our principal finding was that APOE e4 significantly asso-
ciated with increased WM hyperintensity volumes. In future,
UK Biobank will include biomarker and serum lipid data.
These data may be used to inform part of the causal chain
from APOE genotype (a lipid transporter gene) to cognitive/
brain phenotypes. While this report includes MRI and genetic
data on around 10,000 participants from UK Biobank, ulti-
mately around 100,000 will have data on these by around
2023 (Miller et al. 2016); this will permit even greater statis-
tical power in future with which to detect such effects with
greater reliability still.
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